Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/BOR.0b013e32836437ba http://scihub22266oqcxt.onion/10.1097/BOR.0b013e32836437ba C4878999!4878999 !23872903     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=23872903 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\23872903 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Curr+Opin+Rheumatol 2013 ; 25 (5 ): 584-90 Nephropedia Template TP {{tp|p=23872903 |t=2013. Update on pathogenesis and treatment of CLE |pdf=|usr=}}{{23872903 }} gab.com Text Update on pathogenesis and treatment of CLE JO: Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=23872903 #FOAvip PURPOSE OF REVIEW: Cutaneous Lupus Erythematous (CLE) is an autoimmune disease in which patients may present with isolated skin findings or have CLE associated with underlying systemic disease. The most significant recent studies on its pathogenesis and therapeutic management are reviewed here. RECENT FINDINGS: Patients with subacute and Discoid Lupus Erythematous had elevated Interferon score, about a third of all cases of SCLE could be attributed to previous drug exposure, and smoking may be more closely associated with CLE than Systemic Lupus Erythematous (SLE). An underlying genetic defect in some subsets of CLE patients may also be shared with SLE. Efficacy of antimalarial therapy is enhanced by increasing treatment duration or maintaining higher blood drug concentrations. Combination antimalarials that include quinacrine, thalidomide analogs, and Mycophenalate Mofetil may also be effective in refractory CLE. SUMMARY: The pathogenesis of CLE remains unclear, and is likely multifactorial. Identified associations with subsets of CLE suggest future research questions in CLE pathogenesis. Subsets of CLE associated with interface dermatitis may share an underlying genetic defect in interferon signaling with SLE. The Cutaneous Lupus Disease Area and Severity Index is a valuable and widely used tool allowing standardized assessment and reporting of cutaneous disease activity and damage. More evidence is available to guide treatment of refractory CLE, but larger studies are needed. VIDEO ABSTRACT: http://links.lww.com/COR/A4. Twit Text FOAVip Update on pathogenesis and treatment of CLE ????Curr Opin Rheumatol http://www.kidney.de/pget.php?&tw=1&pmid=23872903 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23872903 #FOAvip English Wikipedia <ref>{{Cite pmid|23872903 }}</ref> Update on pathogenesis and treatment of CLE #MMPMID23872903 Privette ED ; Werth VP Curr Opin Rheumatol 2013[Sep]; 25 (5 ): 584-90 PMID23872903 show ga PURPOSE OF REVIEW: Cutaneous Lupus Erythematous (CLE) is an autoimmune disease in which patients may present with isolated skin findings or have CLE associated with underlying systemic disease. The most significant recent studies on its pathogenesis and therapeutic management are reviewed here. RECENT FINDINGS: Patients with subacute and Discoid Lupus Erythematous had elevated Interferon score, about a third of all cases of SCLE could be attributed to previous drug exposure, and smoking may be more closely associated with CLE than Systemic Lupus Erythematous (SLE). An underlying genetic defect in some subsets of CLE patients may also be shared with SLE. Efficacy of antimalarial therapy is enhanced by increasing treatment duration or maintaining higher blood drug concentrations. Combination antimalarials that include quinacrine, thalidomide analogs, and Mycophenalate Mofetil may also be effective in refractory CLE. SUMMARY: The pathogenesis of CLE remains unclear, and is likely multifactorial. Identified associations with subsets of CLE suggest future research questions in CLE pathogenesis. Subsets of CLE associated with interface dermatitis may share an underlying genetic defect in interferon signaling with SLE. The Cutaneous Lupus Disease Area and Severity Index is a valuable and widely used tool allowing standardized assessment and reporting of cutaneous disease activity and damage. More evidence is available to guide treatment of refractory CLE, but larger studies are needed. VIDEO ABSTRACT: http://links.lww.com/COR/A4. |Administration, Cutaneous [MESH] |Antibodies, Monoclonal/therapeutic use [MESH] |Antimalarials/therapeutic use [MESH] |Genetic Predisposition to Disease [MESH] |Humans [MESH] |Immunosuppressive Agents/therapeutic use [MESH] |Lupus Erythematosus, Cutaneous/*drug therapy/*etiology/genetics [MESH]Update on pathogenesis and treatment of CLE (epmc).pdf DeepDyve Pubget Overpricing